JPRN-UMIN000001672已完成2 期
A prospective clinical phase II study of allogeneic stem cell transplantation using conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for patients with acute lymphoblastic leukemia. - Allo-SCT using conditioning with medium-dose VP/CY/TBI for ALL (C-SHOT 0901)
Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine0 个研究点目标入组 50 人开始时间: 2009年1月31日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 50years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.ALL L3 (Burkitt leukemia) 2. Positivity for HBs antigen and/or HCV antibody and/or HIV antibody 3. Double cancers 4. Infection that need to be treated 5. Severe mental disorder 6. Pregnant or breast-feeding woman 7. Uncontrolled diabetes mellitus even by insulin treatment 8. Myocardial infarction or heart failure 9. Liver cirrhosis 10. Body mass index more than 35 11. Severe arrhythmia 12. Having pentostatin 13. Severe allergy for VP-16 or cyclophosphamide 14.An inappropriate patient judged by the medical attendant
研究者
相似试验
已完成
2 期
Randomized phase II study of allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using once daily intravenous busulfan and cyclophosphamide as conditioning regimeacute myeloid leukemia(AML) myelodysplastic syndrome(MDS) chronic myelogenous leukemia(CML)JPRN-UMIN000009762Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital68
招募中
1 期
Evaluation of the safety and efficacy of allogeneic activated Natural killer cells in metastatic Colon AdenocarcinomaIRCT20230704058675N1Middle East Gene Therapy corporation10
已完成
1 期
Evaluation of the safety and efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) using alemtuzumab for patients with aplastic anemiaAplastic anemiaJPRN-C000000356GCP-ISS HE0403 group38
进行中（未招募）
1 期
Phase II trial of peripheral blood stem cell transplantation from a partially compatible family donor in patients with a blood tumor (myelodysplasia and leukemia) treated for the prevention of fungal infections with posaconazoleMyelodisplastic Syndrome (MDS) and AcuteLeukemiaMedDRA version: 20.0Level: LLTClassification code 10028532Term: MyelodysplasiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10024289Term: Leukaemia acuteSystem Organ Class: 100000004864EUCTR2017-004423-78-ITOSPEDALE SAN RAFFAELE82
招募中
2 期
AML-SCT15acute myeloid leukemia (AML)JPRN-jRCTs051180190YABE Hiromasa66